Ehlers-Danlos syndrome
MONDO:0020066
The Ehlers–Danlos syndromes (EDS) are a clinically and genetically heterogeneous group of heritable connective tissue disorders (HCTDs) characterized by joint hypermobility, skin hyperextensibility, and tissue fragility.
Research intelligence
Directly mapped studies only · unique clinical trialsCurrent registry observations. Phase counts may overlap. Study start dates are not registry registration dates. Investigational interventions are not approved-treatment recommendations.
Medications under investigation
Verified disease and drug mappings that co-occur within the same study; not evidence of effectiveness.
MONDO disease family
Recruiting studies by city
Trial status
Trial phase
Study start year
Investigated drug interventions
Ehlers–Danlos syndrome
Ehlers–Danlos syndromes (EDS) are a group of 13 genetic connective tissue disorders. Symptoms often include loose joints; joint pain; stretchy, velvety skin; and abnormal scar formation. These may be noticed at birth or in early childhood. Complications may include aortic dissection, joint dislocations, scoliosis, chronic pain, or early osteoarthritis. The existing classification was last updated in 2017, when a number of rarer forms of EDS were added. EDS occurs due to mutations in one or more of the 19 particular genes which can contribute to the condition. The specific gene affected determines the type of EDS, though the genetic causes of hypermobile Ehlers–Danlos syndrome (hEDS) are still unknown. Some cases result from a new variation occurring during early development. In contrast, others are inherited in an autosomal dominant or recessive manner. Typically, these variations result in defects in the structure or processing of the protein collagen or tenascin. Diagnosis is often based on symptoms, particularly hEDS, but people may initially be misdiagnosed with somatic symptom disorder, depression, or myalgic encephalomyelitis/chronic fatigue syndrome. Genetic testing can be used to confirm all types of EDS except hEDS, for which a genetic marker has yet to be discovered. A cure is not yet known, and treatment is supportive in nature. Physical therapy and bracing may help strengthen muscles and support joints. Several medications can help alleviate symptoms of EDS, such as pain and blood pressure drugs, which reduce joint pain and complications caused by blood vesse...
Background only. Canonical identity remains MONDO; clinical-trial relationships come from ClinicalTrials.gov.Clinical trials
3 shownDrugs being studied
Leading sponsors
Disease identity and terminology: MONDO. Trial relationships: ClinicalTrials.gov.